Epirubicin

FDA Approved: * September 15, 2006
Pharm Company: * MAYNE PHARMA USA
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Epirubicin Overview

Epirubicin is an anthracycline drug used for chemotherapy. It can be used in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. It is marketed by Pfizer under the trade name Ellence in the US and Pharmorubicin or Epirubicin Ebewe elsewhere. Similarly to other anthracyclines, epirubicin acts by intercalating DNA strands. Intercalation results in complex formation which inhibits DNA and RNA synthesis. It also triggers DNA cleavage b...

Read more Epirubicin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Epirubicin

Recent Epirubicin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Epirubicin
  • Injection: 200mg, 200mg/100ml (2mg/ml), 200mg/vial, 2mg/ml, 2mg/ml (200mg/100ml), 2mg/ml (50mg/25ml), 50mg, 50mg/25ml (2mg/ml), 50mg/vial
  • Powder: 200mg/vial, 50mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Epirubicin: (22 results)

Showing the first 20, Sorted by National Drug Code
  • 0115-1675 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection by Impax Generics
  • 0143-9202 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection by West-ward Pharmaceuticals Corp
  • 0143-9203 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection by West-ward Pharmaceuticals Corp
  • 0703-3067 Epirubicin Hydrochloride 50 mg/25ml Intravenous Injection, Solution by Teva Parenteral Medicines, Inc.
  • 0703-3069 Epirubicin Hydrochloride 200 mg/100ml Intravenous Injection, Solution by Teva Parenteral Medicines, Inc.
  • 25021-203 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection by Sagent Pharmaceutical
  • 45963-608 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection by Actavis Pharma, Inc.
  • 53104-0211 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection by Cipla Limited
  • 53150-247 Epirubicin Hydrochloride 200 mg/100ml Intravenous Injection by Amneal-agila, LLC
  • 53150-250 Epirubicin Hydrochloride 50 mg/25ml Intravenous Injection by Amneal-agila, LLC
  • 55390-207 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection, Solution by Bedford Laboratories
  • 55390-208 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection, Solution by Bedford Laboratories
  • 59762-5091 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection, Solution by Greenstone, LLC
  • 59762-5093 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection, Solution by Greenstone, LLC
  • 59923-701 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection by Areva Pharmaceuticals, Inc.
  • 61703-347 Epirubicin Hydrochloride 50 mg/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Hospira Worldwide, Inc.
  • 61703-348 Epirubicin Hydrochloride 200 mg/100ml Intravenous Injection, Powder, Lyophilized, for Solution by Hospira Worldwide, Inc.
  • 61703-359 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection, Solution by Hospira Worldwide, Inc.
  • 63323-151 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection, Solution by Fresenius Kabi USA, LLC
  • 66758-042 Epirubicin Hydrochloride 2 mg/ml Intravenous Injection, Solution by Sandoz Inc
  • 2 more results ...

Other drugs which contain Epirubicin or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 25 March 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA